Market closedNon-fractionalADR
I-MAB/IMAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About I-MAB
I-Mab is a global biotech company. The Company is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.
Ticker
IMAB
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
Rockville, United States
Employees
220
Website
www.i-mabbiopharma.com
I-MAB Metrics
BasicAdvanced
$134M
Market cap
-
P/E ratio
-$2.43
EPS
1.09
Beta
-
Dividend rate
Price and volume
Market cap
$134M
Beta
1.09
52-week high
$3.38
52-week low
$1.16
Average daily volume
4.8
Financial strength
Current ratio
5.674
Total debt to equity
1.744
Interest coverage (TTM)
-42.63%
Management effectiveness
Return on assets (TTM)
-43.84%
Return on equity (TTM)
-63.34%
Return on investment (TTM)
-53.14%
Valuation
Price to revenue (TTM)
35.125
Price to book
0.564
Price to tangible book (TTM)
0.607
Growth
Revenue change (TTM)
112.48%
Earnings per share change (TTM)
42.00%
3-year revenue growth
-73.83%
What the Analysts think about I-MAB
Analyst Ratings
Majority rating from 4 analysts.
I-MAB Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
¥7.9M
-59.69%
Net income
-¥693M
-10.34%
Profit margin
-8,769.62%
122.45%
I-MAB Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q3 22
Actual
-
Expected
-$0.49
Surprise
-
I-MAB News
AllArticlesVideos
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
PRNewsWire·1 month ago
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024
GlobeNewsWire·1 month ago
I-Mab to Participate at the Jefferies Global Healthcare Conference
PRNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for I-MAB stock?
I-MAB (IMAB) has a market cap of $134M as of July 06, 2024.
What is the P/E ratio for I-MAB stock?
The price to earnings (P/E) ratio for I-MAB (IMAB) stock is 0 as of July 06, 2024.
Does I-MAB stock pay dividends?
No, I-MAB (IMAB) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next I-MAB dividend payment date?
I-MAB (IMAB) stock does not pay dividends to its shareholders.
What is the beta indicator for I-MAB?
I-MAB (IMAB) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell I-MAB stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.